“I am pleased with what our team was able to accomplish in 2023 and am excited to kick off 2024 with important company milestones ahead,” said Joel Becker, President and Chief Executive Officer of NeuroPace. “We remain focused on growth within our current market, market and indication expansion, and execution of our product development and clinical initiatives, while delivering strong gross margin performance and demonstrating continued operating discipline. I am also pleased to announce that we have completed not only enrolling, but also implanting the number of patients required for FDA submission in our NAUTILUS pivotal trial more than a quarter early, which we believe is a testament to the interest in extending the benefits of our RNS System to patients suffering from generalized epilepsy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NPCE:
- NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
- NeuroPace ‘primed for continued outperformance’ in 2024, says Lake Street
- NeuroPace announces early completion of patient enrollment in NAUTILUS study
- NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
- NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Questions or Comments about the article? Write to editor@tipranks.com